Genmab

	7/2 11:22 af E L	we'll see how that works out for Tepezza SC, we don't know if the contracts are similar, but at at least Genmab now knows how to proceed with a potential arbitrage :-D The news in itself is not real news in that Horizon was looking at SC already in 2020 with Halozyme, but i imagine Xeris Biopharma will run with the deal after this (link)
	7/2 10:46 af Sukkeralf	(link)
	7/2 10:46 af Sukkeralf	Lundbeck igangsætter fase 3-studie med Lu AF82422.
	7/2 10:41 af Sukkeralf	But Amgen seems to being doing a good job - thats so good :-)
	7/2 10:40 af Sukkeralf	UUHFFF - now we hate these sc versions :-(
	7/2 10:01 af E L	The Company plans to initiate a Phase 3 study evaluating the subcutaneous route of administration of TEPEZZA in patients with TED in H1 2024.
	7/2 10:01 af E L	In December 2023, TEPEZZA received orphan drug designation in Japan for patients with moderate to severe active thyroid eye disease (TED). A New Drug Application was submitted for TEPEZZA in Japan based on the results from the OPTIC-J study evaluating TEPEZZA in patients with active TED. A Phase 3 study of TEPEZZA in Japan for chronic or low clinical activity score (CAS) TED continues to enroll patients.
	7/2 10:00 af E L	AMGEN: TEPEZZA® (teprotumumab-trbw) generated $448 million of sales for the period. TEPEZZA is the first and only FDA-approved treatment for thyroid eye disease (TED). -Sales figures reflect only sales in the period from Oct. 6 2023 through the end of the year, and not the full quarter. (link)
	7/2 08:32 af LP90	God morgen :-)
	7/2 08:12 af Stroka	God morgen :-)
	7/2 07:23 af Plimsoller	God morgen :-)
	7/2 07:06 af Helge Larsen/PI-redaktør	Godmorgen :-)
	6/2 17:31 af Bulder	En vis konkurrence - i 2. linje. 1/3 får grad 3 eller værre problemer med synet.
	6/2 17:18 af KWC	GSK’s Blenrep Combo Scores Phase III Win in Multiple Myeloma
	6/2 17:18 af KWC	Konkurence ? (link)
	6/2 17:18 af Bulder	Sc hex 38 er i hvert fald et nyt statement. Winkel er blevet spurgt flere gange, og sagt, at det var for tidligt at afgøre.
	6/2 16:40 af gdn55	Er dette ikke en dansk chat?
	6/2 16:23 af Teller	You not only have to be a good scientist and be able to develop new and wonderful drugs. You also and importantly have to be extremely "Street-smart" in a legal sense.
	6/2 16:22 af w	Hi Martin, Hexabody CD38 is currently intravenous but can be made to SC by JnJ
	6/2 16:22 af w	i asked Carlsen about this, regarding a sub version
	6/2 16:17 af Teller	To be honest - My greatest concern is the deal made on super Dara. Was the same lawyers used for this deal??
	6/2 15:55 af E L	GEN1046 Safety Trial has gone from Recruiting -to - Active, not recruiting (link)
	6/2 14:02 af JørgenVarnæs	When Verdult says he still has respect for GEN leadership - but dara has been gifted to the partner and hexacd38 is closed country, he is really saying - there is not much respect left
	6/2 13:59 af JørgenVarnæs	No? I beg to differ

	6/2 13:57 af Bulder	Genmab is not to be blamed for the current Price. It’s not Long ago it was +3000. Business hasn’t changed since then.
	6/2 13:46 af JørgenVarnæs	Am I completely wrong in saying, that the current GEN valuation is made up ENTIRELY from cash and expected dara-derived royalties?
	6/2 13:45 af JørgenVarnæs	Please note, that I'm not questioning the quality of the research - I'm questioning the business decisions following the research
	6/2 13:44 af Bulder	You cannot put a finger on the Scientific side of genmab. It’s been an unprecedented world class succes. Their wiilingness to pay out to shareholders however is far from satisfying.
	6/2 13:31 af JørgenVarnæs	Its time GEN starts earning its keep for the shareholders
	6/2 13:30 af JørgenVarnæs	Seriously - take out dara and cash from the valuation and you are left with dust and tubleweeds. Is that the hallmark of a successful R&D organization?
	6/2 13:29 af Sukkeralf	I think you are unbelievable harsh in your criticism of Genmab JV - its still one of the most successful biotechs in Europe
	6/2 13:12 af JørgenVarnæs	GEN hasn't missed one single step in messing up values
	6/2 13:12 af JørgenVarnæs	Better deals were possible every step of the way
	6/2 13:08 af E L	which is why they want 50/50 partnerships in the future. which they hope to get from the stronger position they are in now. beter deals were not possible in the past , unfortunately
	6/2 13:02 af JørgenVarnæs	KYSO must be about how much value GEN leaves on the table for the partners
	6/2 13:02 af JørgenVarnæs	...with how much ownership? GEN is being traded as a bond with the royalties from dara and the cash holding as a foundation. Other than that, there is very little of value in the valuation
	6/2 12:56 af E L	Kesimpta, tepezza, tisotumab, talquetamab, teclistamab, amivantamab, these are not little drugs. the technology is there. But there is nobody that can guarantee a repeat, that is true.
	6/2 12:49 af JørgenVarnæs	here we are in year 24 of GENs existence - CD38 is closed country, cd3cd20 is heavily contested by Roche - and little else to show
	6/2 12:48 af JørgenVarnæs	...because data wasn't deemed to be very KYSO - in fact the data has changed market sentiment away from opt-in.
	6/2 12:46 af E L	and to remind you , bringing out the early data on HexaCD38 wasn't exactly a very big success lol. my guess is that they will actually become even more carefull bringing out new data...
	6/2 12:44 af E L	It comes when the data is ready , and preferably at a medical conference
	6/2 12:44 af E L	ok, we would all like to hear that, but you know that there is a very small chance that we will get info on that at the earnings report.
	6/2 12:16 af JørgenVarnæs	Is there anything there? We don't know
	6/2 12:16 af JørgenVarnæs	We have heard about solid tumors for quite some time now - but only seen glimpses of effect from tisutomab
	6/2 12:15 af JørgenVarnæs	What is the promise of the early stage pipeline? We have no idea
	6/2 12:15 af JørgenVarnæs	Sure - I want to see signs of clinical effect coming out of phase 1 programs. So far we get nothing or vailed references to synergistic effect
	6/2 12:12 af E L	what do you expect from them then, concretely? because the only way i can imagine them proving this to you is to grind through these early stage programs into maturity and hopefully approval. i don't know how else they can do this? isn't that what biotech is all about?
	6/2 12:05 af JørgenVarnæs	I'm looking for a more direct connection between development cost and clinical effect - till now a lot of money has been thrown at early stage programs with no visible effect. This has forced analysts to consider development initiatives as pure loss-giving activities - maybe this is why Genmab is considered a cost sinkhole by the market...?
	6/2 11:59 af E L	could well be. not easy to estimate this guidance either, not so sure what to expect from the cost side. Actually their first Darzalex guidance last year was quite good in hindsight, with a mid point of 9.7bn
	6/2 10:56 af Sukkeralf	It seems like we need to get guidance out of the way before fokus will be on data and alike